Tags

Type your tag names separated by a space and hit enter

Management of the depressive component of bipolar disorder.
Depress Anxiety. 1996-1997; 4(4):190-8.DA

Abstract

Acute bipolar depression (ABD) and breakthrough depression occurring during maintenance therapy of bipolar disorder are associated with significant morbidity and an increased risk of suicide. Lithium is an effective mood stabilizer for ABD, but its onset of antidepressant action is slow and additional antidepressant therapy is often prescribed. The extent to which other mood stabilizers (e.g., carbamazepine and valproate) have antidepressant activity is unclear. Preliminary initial research suggests three potential advantages that selective serotonin reuptake inhibitors have over tricyclic antidepressant for ABD: possibly greater efficacy, fewer adverse effects, and a lower frequency of antidepressant-induced mania. Bupropion may also have significant advantages. However, further research is needed to confirm these findings. Monoamine oxidase inhibitors are the antidepressant of choice for atypical bipolar depression. Electroconvulsive therapy (ECT) has the highest response rate of all treatments for ABD. Further research is needed to explore combination treatments with mood stabilizers and antidepressants for the effective treatment of ABD.

Authors+Show Affiliations

Department of Psychiatry, University of Wisconsin, Madison 53719, USA.

Pub Type(s)

Comparative Study
Journal Article
Review

Language

eng

PubMed ID

9166651

Citation

Kalin, N H.. "Management of the Depressive Component of Bipolar Disorder." Depression and Anxiety, vol. 4, no. 4, 1997, pp. 190-8.
Kalin NH. Management of the depressive component of bipolar disorder. Depress Anxiety. 1997;4(4):190-8.
Kalin, N. H. (1997). Management of the depressive component of bipolar disorder. Depression and Anxiety, 4(4), 190-8.
Kalin NH. Management of the Depressive Component of Bipolar Disorder. Depress Anxiety. 1996-1997;4(4):190-8. PubMed PMID: 9166651.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Management of the depressive component of bipolar disorder. A1 - Kalin,N H, PY - 1996/1/1/pubmed PY - 1996/1/1/medline PY - 1996/1/1/entrez SP - 190 EP - 8 JF - Depression and anxiety JO - Depress Anxiety VL - 4 IS - 4 N2 - Acute bipolar depression (ABD) and breakthrough depression occurring during maintenance therapy of bipolar disorder are associated with significant morbidity and an increased risk of suicide. Lithium is an effective mood stabilizer for ABD, but its onset of antidepressant action is slow and additional antidepressant therapy is often prescribed. The extent to which other mood stabilizers (e.g., carbamazepine and valproate) have antidepressant activity is unclear. Preliminary initial research suggests three potential advantages that selective serotonin reuptake inhibitors have over tricyclic antidepressant for ABD: possibly greater efficacy, fewer adverse effects, and a lower frequency of antidepressant-induced mania. Bupropion may also have significant advantages. However, further research is needed to confirm these findings. Monoamine oxidase inhibitors are the antidepressant of choice for atypical bipolar depression. Electroconvulsive therapy (ECT) has the highest response rate of all treatments for ABD. Further research is needed to explore combination treatments with mood stabilizers and antidepressants for the effective treatment of ABD. SN - 1091-4269 UR - https://www.unboundmedicine.com/medline/citation/9166651/Management_of_the_depressive_component_of_bipolar_disorder_ L2 - https://doi.org/10.1002/(SICI)1520-6394(1996)4:4<190::AID-DA5>3.0.CO;2-J DB - PRIME DP - Unbound Medicine ER -